Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance

Oncogene

Volumn 36, Issue 15, 2017, Pages 2131-2145

  Yu, T ^a,b,c   Yang, G ^a   Hou, Y ^b   Tang, X ^b   Wu, C ^a   Wu, X A ^a   Guo, L ^a   Zhu, Q ^a   Luo, H ^d   Du, Y E ^b   Wen, S ^b   Xu, L ^b   Yin, J ^b   Tu, G ^a   Liu, M ^b  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c Jiangxi Cancer Hospital   (China)

^d THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIRUBICIN; EXPORTIN 1; FLUORODEOXYGLUCOSE F 18; G PROTEIN COUPLED ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOLYTIC ENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE B; LACTIC ACID; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE KINASE 4; PYRUVIC ACID; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; CELL RECEPTOR; CREB1 PROTEIN, HUMAN; ESTROGEN RECEPTOR; EXPORTIN 1 PROTEIN; GPER PROTEIN, HUMAN; KARYOPHERIN;

AEROBIC GLYCOLYSIS; ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; ENERGY METABOLISM; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; ACTIVE TRANSPORT; BREAST TUMOR; CYTOPLASM; DRUG RESISTANCE; FEMALE; FIBROBLAST; GLYCOLYSIS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; STROMA CELL; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLASTS; GLYCOLYSIS; HUMANS; KARYOPHERINS; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; STROMAL CELLS;

EID: 84990990016     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.370     Document Type: Article

References (60)

1. Fan L, Strasser-Weippl K, Li JJ St, Louis J, Finkelstein DM, Yu KD et al. Breast cancer in China. Lancet Oncol 2014; 15: e279-e289.
2. Kalluri R. Basement membranes: structure, assembly and role in tumour angio-genesis. Nat Rev Cancer 2003; 3: 422-433.
3. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 2011; 125: 687-696.
4. Ahn S, Cho J, Sung J, Lee JE, Nam SJ, Kim KM et al. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol 2012; 33: 1573-1580.
5. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394-406.
6. Tang X, Hou Y, Yang G, Wang X, Tang S, Du YE et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ 2016; 23: 132-145.
7. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
8. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
9. Scaling AL, Prossnitz ER, Hathaway HJ. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 2014; 5: 146-160.
10. Yu T, Liu M, Luo H, Wu C, Tang X, Tang S et al. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells. J Steroid Biochem Mol Biol 2014; 143: 392-403.
11. Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res 2013; 15: R114.
12. Luo H, Yang G, Yu T, Luo S, Wu C, Sun Y et al. GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts. Endocr Relat Cancer 2014; 21: 355-369.
13. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S et al. GPER mediates activation of HIF1α/VEGF signaling by estrogens. Cancer Res 2014; 74: 4053-4064.
14. Luttrell LM, Daaka Y, Lefkowitz RJ. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 1999; 11: 177-183.
15. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008; 70: 165-190.
16. Fujiwara S, Terai Y, Kawaguchi H, Takai M, Yoo S, Tanaka Y et al. GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. J Ovarian Res 2012; 5: 35.
17. Girgert R, Emons G, Gründker C. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17beta-estradiol. BMC Cancer 2014; 14: 935.
18. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006; 2: 207-212.
19. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009; 5: 421-427.
20. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 2010; 123: 87-96.
21. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006; 12: 6359-6366.
22. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 2011; 128: 457-466.
23. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17β-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010; 70: 6036-6046.
24. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007; 148: 3236-3245.
25. Cheng SB, Graeber CT, Quinn JA, Filardo EJ. Retrograde transport of the trans-membrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 2011; 76: 892-896.
26. Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 2012; 153: 2953-2962.
27. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 2009; 69: 5415-5423.
28. Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, Abonante S et al. The nuclear localization signal is required for nuclear GPER translocation and function in breast cancer-associated fibroblasts (CAFs). Mol Cell Endocrinol 2013; 376: 23-32.
29. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
30. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8: 3984-4001.
31. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C et al. Anti-estrogen resistance in breast cancer is induced by the tumor micro-environment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 2011; 12: 924-938.
32. Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F. Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle 2012; 11: 3956-3963.
33. DeFranco DB. Nuclear export: DNA-binding domains find a surprising partner. Curr Biol 2001; 11: R1036-R1037.
34. Lombardi M, Castoria G, Migliaccio A, Barone MV, Di Stasio R, Ciociola A et al. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol 2008; 182: 327-340.
35. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90: 1051-1060.
36. Ji JY, Jing H, Diamond SL. Shear stress causes nuclear localization of endothelial glucocorticoid receptor and expression from the GRE promoter. Circ Res 2003; 92: 279-285.
37. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 2003; 17: 628-642.
38. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001; 2: 599-609.
39. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 2005; 102: 4459-4464.
40. Kim MY, Koh DI, Choi WI, Jeon BN, Jeong DY, Kim KS et al. ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65. Nucleic Acids Res 2015; 43: 1609-1625.
41. Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG et al. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2013; 19: 3703-3713.
42. Kitajima K, Fukushima K, Miyoshi Y, Katsuura T, Igarashi Y, Kawanaka Y et al. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. Jpn J Radiol 2016; 34: 220-228.
43. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 15: 1960-1971.
44. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK et al. Evidence for a stromal-epithelial 'lactate shuttle' in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10: 1772-1783.
45. Lapensee EW, Tuttle TR, Fox SR, Ben-Jonathan N. Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-a-positive and-negative breast cancer cells. Environ Health Perspect 2009; 117: 175-180.
46. Liu Y, Du FY, Chen W, Fu PF, Yao MY, Zheng SS. G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30. Am J Transl Res 2015; 7: 967-975.
47. Vivacqua A, De Marco P, Santolla MF, Cirillo F, Pellegrino M, Panno ML et al. Estrogenic gper signaling regulates mir144 expression in cancer cells and cancer-associated fibroblasts (cafs). Oncotarget 2015; 6: 16573-16587.
48. Zucchetti AE, Barosso IR, Boaglio AC, Basiglio CL, Miszczuk G, Larocca MC et al. G-protein-coupled receptor 30/adenylyl cyclase/protein kinase A pathway is involved in estradiol 17|3-d-glucuronide-induced cholestasis. Hepatology 2014; 59: 1016-1029.
49. 18F-misonidazole uptake:a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med 2012; 53: 1262-1268.
50. Farace P, D'Ambrosio D, Merigo F, Galiè M, Nanni C, Spinelli A et al. Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. Eur J Nucl Med Mol Imaging 2009; 36: 616-623.
51. 18F-FDG Uptake in non-small cell lung cancer A549 in mice: a pilot study. J Nucl Med 2015; 56: 607-612.
52. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005; 62: 545-553.
53. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1a/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res 2013; 15: R64.
54. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells 'fuel' cancer cell mitochondria. Cell Metab 2012; 15: 4-5.
55. Alvero AB, Montagna MK, Sumi NJ, Joo WD, Graham E, Mor G. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget 2014; 5: 8703-8715.
56. Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci 2015; 18: 501-510.
57. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7: 423-467.
58. Sotgia F, Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Lisanti MP. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res 2011; 13: 213.
59. Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011; 333: 233-238.
60. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17: 1498-1503.